<code id='BEC8AB628B'></code><style id='BEC8AB628B'></style>
    • <acronym id='BEC8AB628B'></acronym>
      <center id='BEC8AB628B'><center id='BEC8AB628B'><tfoot id='BEC8AB628B'></tfoot></center><abbr id='BEC8AB628B'><dir id='BEC8AB628B'><tfoot id='BEC8AB628B'></tfoot><noframes id='BEC8AB628B'>

    • <optgroup id='BEC8AB628B'><strike id='BEC8AB628B'><sup id='BEC8AB628B'></sup></strike><code id='BEC8AB628B'></code></optgroup>
        1. <b id='BEC8AB628B'><label id='BEC8AB628B'><select id='BEC8AB628B'><dt id='BEC8AB628B'><span id='BEC8AB628B'></span></dt></select></label></b><u id='BEC8AB628B'></u>
          <i id='BEC8AB628B'><strike id='BEC8AB628B'><tt id='BEC8AB628B'><pre id='BEC8AB628B'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:explore    Page View:454
          Stock exchange
          Drew Angerer/Getty Images

          Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development. 

          The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

          advertisement

          In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In